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ABSTRACT: This study is focused on identifying novel epithelial markers in circulating extracellular vesicles (EVs) through the
development of a dual sandwich-type electrochemical paper-based immunosensor for Claudin 7 and CD81 determination, as well as
its validation in breast cancer (BC) patients. This immunosensor allows for rapid, sensitive, and label-free detection of these two
relevant BC biomarkers. Under optimum conditions, the limit of detection for Claudin 7 was 0.4 pg mL−1, with a wide linear range
of 2 to 1000 pg mL−1, while for CD81, the limit of detection was 3 pg mL−1, with a wide linear range of 0.01 to 10 ng mL−1. Finally,
we validated Claudin 7 and CD81 determination in EVs from 60 BC patients and 20 healthy volunteers, reporting higher diagnostic
accuracy than the one observed with classical diagnostic markers. This analysis provides a low-cost, specific, versatile, and user-
friendly strategy as a robust and reliable tool for early BC diagnosis.
■ INTRODUCTION
Breast cancer (BC) is the most common cancer disease among
females all over the world. BC is the principal cause of cancer-
related death in women in less developed countries and the
second leading cause in developed ones.1 Clinical studies
showed that early diagnosis followed by suitable treatments
significantly improved the survival rates.2 Mammography is the
preferred method for BC detection; however, this method
could be less effective in young women with dense breasts.3
Blood-based screenings are cost-effective applications for BC
diagnosis and, unfortunately, a reliable blood marker for
accurate diagnosis at early stages is not available yet.4
Detection of circulating proteins such as carcinoembryonic
antigen (CEA) or cancer antigen 15.3 (CA 15-3) is actually
being employed without proper results in early stages.
Recently, circulating tumor cells, free DNA, and extracellular
vesicles (EVs) have been demonstrated to be very specific
markers for diagnosis, characterization, and monitoring of
cancer disease.5 EVs present several advantages compared to
other liquid biopsy components. Mainly, EVs are released in
early stages of cancer and their structure works as a capsule
that protects the molecular and proteomic cargo. Moreover,
EV isolation is a relatively fast, easy, and robust method.6
EVs are lipid-bilayered vesicles released by a variety of
mammalian cells.7 EVs enclose different types of membrane-
associated proteins, and some of them are specific to the cell
where they were produced.7 Epithelial cancer cells have
increased EV release rates compared to healthy epithelial cells
due to tumor hypoxia,8 endo-lysosomal trafficking disruption,
and cellular stress.9 As a consequence, the percentage of
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epithelial EVs isolated in plasma from epithelial cancer patients
is higher. Unfortunately, epithelial EVs represent a very small
fraction of the total of EVs found in peripheral blood and, for
this reason, one of the main challenges in measuring these
proteins is the development of sensitive and specific analytical
methods.10
Because of outstanding features such as superior selectivity
and sensitivity compared to standard enzyme-linked immuno-
sorbent assay (ELISA) tests, electrochemical immunosensors
have been quickly adopted for the detection of some cancer
markers.11−15 Specifically, in the last years, paper-based
immunosensors have received considerable attention from
the scientific community because of the advantages of low cost,
biocompatibility, ease of storage, portability, and the possibility
of performing chemical analysis using capillary flow without
the need for external pumps.16 Electrochemical detection is
quite promising because of its compatibility with micro-
fabrication techniques, adjustable selectivity, low levels of
detectability, and portability, mainly when used in combination
with battery-powered potentiostats.17 Moreover, different
techniques can be explored to fabricate the electrodes on
paper platforms, including sputtering, screen-printing, stencil-
printing, inkjet-printing, laser scribing, microwire placement,
and direct drawing, among others.13,18−20
Besides, among the least expensive of these devices are the
recently introduced electrochemical microfluidic paper-based
analytical devices (μPADs).21−24 μPADs have the potential to
be good alternatives for point-of-care testing over traditional
glass and polymer-based devices because they are easy to use,
are inexpensive, require small volumes of reagents and sample,
provide rapid analysis, are disposable, can be made from
renewable substrate materials, and are portable.21−23 Channel
fabrication is a crucial step in the development of an effective
μPAD. The fabrication of a hydrophobic barrier is a common
method to define channels in paper devices, and several
techniques have been presented in the literature, such as
photolithography, wax printing, screen printing, and inkjet
printing, among others.21−24
Recently, different kinds of materials have been employed
for the fabrication of electrodes and channel surface
modifications of μPAD for biomolecule immobilization.14,24,25
Accordingly, conductive metal nanoparticles and carbon-based
materials such as carbon nanotubes or graphene are commonly
used. Graphene is a carbon allotrope that has attracted the
attention of the scientific community in recent times. This
material exhibits excellent mechanical, thermal, and electrical
properties and can be used to make electronic devices for a
variety of applications, including sensors.26 As for the
modification of the inner channel surface, SBA-15 is an
ordered mesoporous silica that has attracted intense interest
because of its large surface area, well-defined pore structure,
inertness, nontoxicity, high biocompatibility, and thermal and
hydrothermal stability, which make this material an excellent
immobilization platform for biomolecules.27
A variety of μPAD designs have been developed for some
cancer biomarker applications. Sun and co-workers (2018)
reported a novel rotational paper-based analytical device to
implement multistep electrochemiluminescence immunoas-
says.28 This method was applied to CEA and prostate-specific
antigen (PSA) detection. In addition, the rotational valves are
reusable and the response time can be shortened to a few
seconds, conferring significant advantages to the device in
multistep operations. Wang et al. (2018)29 presented a novel
dual-mode cytosensor based on polyhedral AuPd alloy
nanoparticles and three-dimensional reduced graphene oxide
(rGO) constructed for highly sensitive detection of MCF-7
cells. This paper-based dual-mode cytosensor provided a
reliable pathway for sensitive detection of cancer cells in
clinical applications. Wei et al. (2018) developed a low-cost,
label-free, and highly sensitive and selective electrochemical
aptamer sensor to detect PSA in serum samples using a
disposable μPAD.30 The authors proposed this method as a
new platform for sensitive and point-of-care diagnosis of
prostate cancer.
In this work, a high throughput proteomic analysis of EVs
isolated from seven BC patients and five healthy donors was
performed by reverse phase proteomic array (RPPA)
technology in order to identify an epithelial marker candidate
to be validated in a larger cohort of patient and healthy
volunteers. After the identification of Claudin 7 as an epithelial
marker and CD81 as housekeeping, we developed a dual
sandwich-type electrochemical paper-based immunosensor for
both markers. Finally, the novel biomarker Claudin 7 was
demonstrated to be useful for diagnosis of early stages of BC
from results of experiments carried out in circulating EVs from
a cohort of 60 early BC patients and 20 healthy donors. To the
best of our knowledge, no study based on the present analytical
methodology for BC diagnosis on EV samples has been
reported.
■ EXPERIMENTAL SECTION
All materials, reagents, apparatus, and patients characteristics
are shown in the Supporting Information 1.
EV Isolation and Sample Preparation. EVs were
obtained from plasma of BC and healthy donors. Plasma was
obtained from freshly drawn blood using separate plasma
tubes. Aliquots of each plasma sample were deep-frozen at
storage using liquid nitrogen. All plasma samples were
transported to the laboratory on dry ice within 24 h.
EVs were isolated with qEV columns (IZON, New Zealand)
by size exclusion chromatography (SEC), according to the
manufacturer’s recommended protocol. Eluted fractions
enriched in EVs were concentrated by Nanosep centrifugal
devices with 300 kD membranes (Pall Corporation, USA).
Then, the obtained EVs were lysed with 50 μL of lysis buffer
containing 1% Triton X-100, 50 mmol L−1 Hepes pH 7.40, 150
mmol L−1 NaCl, 1.5 mmol L−1 MgCl2, 1 mmol L
−1 EGTA, 100
mmol L−1 NaF, 10 mmol L−1 Na pyruvate, 1 mmol L−1
Na3VO4, 10% glycerol, and a cocktail of protease and
phosphatase inhibitors (Roche Diagnostics, Mannheim,
Germany). Samples were kept at −80 °C until future analysis.
Characterization of Plasma-Isolated EVs. Isolated EVs
were characterized following the International Society of
Extracellular Vesicles (ISEV) recommendations:31 identifica-
tion of specific EVs by specific markers (CD81 and HSC70)
and the lack of a negative marker (GM130) by western blot
(WB),32 single vesicle analysis by nanoparticle tracking analysis
(NTA), and transmission electron microscopy (TEM). The
detailed procedure is shown in the Supporting Information 2.
Candidate Marker’s Identification by RPPA. EV
samples obtained from BC patients (n = 7) and healthy
donors (n = 5) were submitted to the proteomic facilities of
the MD Anderson Cancer Institute (Texas, USA), following
the facility requirements in order to identify a candidate
epithelial marker to be validated as a diagnostic marker of early
BC. Samples were analyzed in a single slide, according to pre-
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established protocols.33 RPPA procedures are summarized in
the Supporting Information 3.
ELISA Analysis. ELISA determinations were performed
according to specific supplier’s recommendations for Claudin 7
(LSBIO, USA) and CD81 (Biorbyt, UK).
Electrochemical Device Fabrication. A dual electro-
chemical immunosensor device was fabricated to validate the
biomarker candidate. It consists of a microfluidic paper-based
device, where the channels were fabricated by wax printing,
while the electrodes were printed with GO and silver ink.
The GO suspension was obtained from graphite powder
according to the Hummer’s method with some modifica-
tions,34 and the GO ink was fabricated according to a
previously reported method including several modifications.26
Brief descriptions of these procedures are summarized in the
Supporting Information 4 and 5.
The fabrication of the electrochemical paper-based device
was performed according to a previously reported method,20
with slight modifications. First, two electrochemical cells
(containing working, auxiliary, and reference electrodes)
were printed in one side of a 20 × 40 mm Whatman paper
# 1 (one electrochemical cell for each channel) (Figure 1).
The working and auxiliary electrodes were printed using the
GO ink over a silver ink track. The Ag-pseudo reference
electrode was printed using silver ink. The layout of the device
was prepared using the Corel Draw software. The electrodes
consisted of squares with 2 mm side, and the electrode
connections were made by painting with silver ink in order to
ensure the electrical contact with the electrochemical work-
station. The electrochemical reduction of GO to rGO was
performed according to a previously reported method.35
Briefly, the electrode was biased at a fixed potential (−1.4
V) in 0.1 mol L−1 PBS for 900 s. Then, the rGO modified
electrode was washed with Milli-Q water, followed by a dry
step with N2.
The μPAD channels were fabricated on the same side of the
paper by a wax printing technique.19 The channels were
designed using Corel Draw, and the hydrophobic barriers were
delimited by wax over the previously printed electrodes. The
device consists of one inset and one outlet connected by two
parallel channels (each used to detect one biomarker) with a 3
mm width and 20 mm length. After printing, the paper was
heated at 90 °C for 5 min to achieve homogenization of the
hydrophobic walls. Then, in order to generate aldehyde groups
in the paper for the next step (modification of the paper
channel surface), its surface was treated with O2 plasma for 1
min.36
Modification of the Paper Channel Surface. SBA-1537
and amino-functionalized SBA-1538 were synthesized accord-
ing to previously reported procedures (Supporting Information
6). The synthetized amino-functionalized SBA-15 at a 1.5 mg
mL−1 concentration was immobilized on the paper channel
surface (immobilization zone) through covalent binding
between aldehyde groups on the paper and the amino groups
of the SBA-15 microparticles, as shown in Figure 1. First, 10
μL of 5% glutaraldehyde in 0.1 mol L−1 phosphate buffer pH
8.00 was placed in the channel for 2 h at room temperature. In
this step, the amino groups present in the SBA-15 surface react
with aldehyde groups of glutaraldehyde, leaving aldehyde
groups free to interact with the amino groups present in the
Figure 1. Schematic representation of the present study which includes the following: (i) biomarker identification, (ii) design of the
electrochemical paper-based immunosensor surface modification, and (iii) validation of biomarkers with the designed immunosensor.
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capture antibodies. Later, 10 μg mL−1 anti-Claudin 7 and anti-
CD81 solutions prepared in 0.1 mol L−1 PBS were incubated
in their respective immobilization zones in the channel for 12 h
at 4 °C. The platform generated by such an immobilization
procedure was shown to be stable at least for 1 month at 4 °C.
Analytical Procedure for Claudin 7 and CD81
Biomarker Determination. The μPAD was washed with
0.1 mol L−1 PBS, followed by a blocking treatment with 1%
BSA for 30 min to avoid the nonspecific binding on the free
sites. After a washing step with 0.1 mol L−1 PBS, 10 μL of a
previously treated sample was added and incubated in a humid
chamber for 5 min, followed by a washing step. In this step,
Claudin 7 and CD81 present in the sample are immunolog-
ically recognized by the antibodies immobilized in the
respective channel. Later, a new washing step with 0.1 mol
L−1 PBS was carried out in order to eliminate the sample
excess, followed by the addition of 10 μL HRP-anti-Claudin 7
and HRP-anti-CD81 mix for 5 min and a further washing step.
Finally, the substrate solution (1 mmol L−1 H2O2 + 1 mmol
L−1 4-TBC in 0.1 mol L−1 phosphate−citrate buffer pH 5.00)
was added. HRP catalyzes the H2O2 chemical reduction to
H2O, with the subsequent oxidation of catechol (H2Q) to p-
benzoquinone (Q), which is detected by amperometry at +100
mV on the rGO working electrode (Figure 1).
Statistical Analysis. Statistic differences between BC
patients and healthy controls were determined by t-test. The
linear correlation between the two variables was measured by
the Pearson correlation coefficient. The distribution between
categorical variables was assessed by the χ2 test. P-values less
than 0.05 were considered statistically significant. Areas under
receiver operating characteristic (ROC) curves were employed
to assess the specificity and sensitivity.
■ RESULTS AND DISCUSSION
Identification of Claudin 7 in Circulating EVs in the
Early Stage of BC Patients. EVs obtained from two healthy
donors were characterized according to the International
Society of Extracellular Vesicles (ISEV) recommendations.31
TEM analysis reported vesicles with typical morphology and
size between 50 and 150 nm. NTA (Nanosight) showed
particles with 105 nm of size average (mode = 82 nm). Finally,
the WB analysis displayed HSC70 and CD81 specific
expression on isolated EVs and the absence of GM130 (Figure
2).
To identify biomarkers in circulating EVs of early BC-
diagnosed patient, EVs were isolated from plasma of healthy
control subjects (n = 5) and patients with BC (stages II and
III; n = 7) and subsequently analyzed by RPPA technology.
Among differentially expressed proteins, 72 were upregulated
and 113 were downregulated in patients with BC (Figure 3).
Claudin 7 was the most differentially expressed protein in the
BC patient group (p = 9.63 × 10−5), considering the epithelial
Figure 2. TEM image of isolated EVs from patients after purification via SEC. Red arrows show lipoprotein contamination, while black arrows
depict EVs (a). NTA of isolated EVs shows particles with 105 nm of size average (mode = 82 nm), SD is represented as red dot line in the graphic
(b). Western blot image from cell controls and EV lysates (c).
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upregulated ones. Claudin 7 is an epithelial-specific protein
that belongs to epithelial tight junctions and plays an
important role in maintaining cell polarity and regulating cell
permeability. According to recent reports, Claudin 7 is
overexpressed in most BC primary tissues, independent of
BC subtypes and clinical or pathological variables. According
to our findings and bibliographic information about Claudin 7,
we decided to employ this protein as a candidate biomarker in
EVs.
After choosing the candidate biomarker, we focused on
testing CD81 as a housekeeping in EVs. CD81 is a specific
marker for EVs, but unfortunately, it is not expressed in 100%
of plasma EVs. To test whether this tetraspanin is suitable to
correct variations in loading, CD81 was analyzed by ELISA in
all samples submitted to RPPA. Then, CD81 values were
compared with the median obtained by RPPA for each sample
and an excellent correlation between both parameters was
found (Pearson r = 0.9991, p < 0.0001) (Supporting
Information 7), demonstrating that CD81 is a suitable protein
for the normalization of Claudin 7 expression in EVs.
Characterization of Synthesized SBA-15. SBA-15 was
morphologically characterized by scanning electron micros-
copy (SEM) and TEM (Figure 4). SBA-15 particles elongated
with a 1.0 ± 0.2 μm length and 400 ± 50 nm width can be
noticed in the SEM micrograph of the paper modified with
SBA-15 (Figure 4a). The TEM micrograph of SBA-15 shows
the typical hexagonal structure and pore homogeneity of this
mesoporous material (Figure 4b).
The SBA-15 N2 adsorption−desorption isotherm is shown
in Figure 4c, and the type IV isotherm with a H1 type
hysteresis is typical of mesoposorous materials with well-
defined cylinder-like pore channels and with uniform pore size.
The inset of Figure 4c shows that the SBA-15 pore size
distribution is narrow (8 nm width).
SBA-15 textural properties were as follows: SBET: 890 m
2 g−1,
VμP: 0.05 cm
3 g−1, VPMP: 0.55 cm
3 g−1, and VTP: 1.12 cm
3 g−1.
A Fourier-transform infrared (FTIR) study was performed to
confirm the SBA-15 amino functionalization, and results
presented in Figure 4d show the changes in the Si−O−Si
(460 cm−1), N−H (690 cm−1), Si−O−Si (800 cm−1), Si−OH
(965 cm−1), C−N, Si−O−Si, Si−CH2−R (1220 cm−1), NH3+
(1555 cm−1), H−O−H (1645 cm−1), and −OH (3500 cm−1)
peaks.
Characterization of rGO Electrodes. The morphological
characterization of the rGO electrode surface was carried out
by SEM. Figure 5a shows a uniform rGO spread over the paper
surface, indicating that the ink suspension is homogeneous.
Figure 5b shows the energy dispersive spectra of (I) GO and
(II) rGO, and the decrease in the oxygen amount in the rGO
confirms the reduction of oxygenated functional moieties.
The electrochemical behavior of the rGO electrode was
examined to ensure its performance. Catechol was used as a
probe because the electron-transfer process associated with this
molecule is fast and well-known. Figure 5c shows a cyclic
voltammogram recorded in 1 mmol L−1 catechol + 0.1 mol L−1
phosphate−citrate buffer pH 5.00 and the typical reversible
process corresponding to the anodic oxidation of catechol to p-
benzoquinone at +414 mV, and the subsequent cathodic
reduction at +334 mV confirms the excellent electrical
conductivity of rGO. Moreover, a study of the influence of
the scan rate on the peak current was performed in the 25−200
mV s−1 range (Figure 5d). The linear relationship between the
peak current values and the square root of the scan rate (inset
of Figure 5d) demonstrates that the catechol overall electron-
transfer process over the rGO surface is mass transport-
controlled.
The electrochemical surface area was calculated by the
Randles−Sevcik equation.39
ν= ×I AD n C2.69 10p
5 1/2 3/2 1/2
where Ip is the peak current in amps, A is the electrode area in
cm2, D is the diffusion coefficient in cm2 s−1, n is the number of
electrons transferred in the electron transfer process, ν is the
scan rate in V s−1, and C is the concentration in mol L−1, and
the value was found to be 0.239 cm2.
Optimization of Experimental Parameters. A system-
atic investigation was performed to optimize the experimental
parameters that affect the biomarker determination in real
samples. This was accomplished by using a 500 pg mL−1
Claudin 7 solution, and the following parameters were studied:
pH and concentration of antibody, SBA-15, and GO ink
(Supporting Information 8).
Analytical Performance for Claudin 7 and CD81
Biomarker Determination. Claudin 7 and CD81 biomarker
determination was carried out under the optimized conditions
using the dual electrochemical paper immunosensor, and the
results were compared with those obtained with the
Figure 3. VENN diagram summarizing RPPA analysis, where 72
proteins were enriched in healthy control and 113 enriched in EVs
from BC patients (a). Box plot showing epithelial markers
significantly highly expressed in patients (Claudin 7 p value = 9.6 ×
10−5, epithermal growth factor receptor (EGFR) p value = 2.4 × 10−4,
estrogen receptor (ER) p value = 4.4 × 10−3, HER3 p value = 6.1 ×
10−4) (b). Values represent concentration related to the average of all
samples.
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commercial ELISA kit for each BC biomarker. The Claudin 7
calibration curve was prepared using standard solutions, with
concentrations ranging from 0.5 to 1200 pg mL−1, and a linear
relationship was observed between 2 and 1000 pg mL−1. The
linear regression equation was I (nA) = 6.69 + 0.24 CClaudin 7,
with a linear regression coefficient R = 0.998 (Supporting
Information 9). The coefficient of variation (CV %) for the
determination of 500 pg mL−1 Claudin 7 was 3.75% (n = 5). A
similar calibration plot was obtained for Claudin 7 by using the
ELISA kit, and the linear regression equation was A = 0.17 +
0.01 CClaudin 7, R = 0.996, and the CV % was 7.32%. The
correlation between the results obtained by using the
electrochemical paper immunosensor and the reference
method (ELISA) was also assessed in EV samples of patients
in a double-blinded experiment, which was performed by two
independent researchers. Figure 6a shows the straight line with
a slope of 1.01, indicating good correspondence between both
methods. The limit of detection (LOD) values for the μPAD
and the commercial ELISA kit were 0.4 and 3.9 pg mL−1,
respectively. The precision of the developed method was
evaluated using Claudin 7 standards. The within-assay
precision was tested by five measurements on the same day.
These analyses were repeated for 3 consecutive days to
estimate the between-assay precision. The developed immu-
nosensor showed good precision; the CV within-assay and
between-assay values were below 3.96 and 6.14%, respectively.
The CD81 calibration plot was prepared using standard
solutions in the concentration ranging from 0.005 to 10 ng
mL−1. A linear relationship was observed between 0.01 and 10
ng mL−1. The linear regression equation was I (nA) = 5.40 +
23.78 CCD81, with a linear regression coefficient R = 0.998
(Supporting Information 9). The CV % for the determination
of 5 ng mL−1 CD81 was 3.66% (n = 5). Parallel measurements
with the ELISA test yielded a calibration plot whose linear
regression equation was A = 0.08 + 0.26 CCD81, R = 0.997, and
the CV % was 6.65%. To validate the proposed immunosensor
method, a comparison was performed with the results of CD81
determinations obtained with the ELISA test. The slope close
to 1 (Figure 6b) demonstrated a good correspondence
between the immunosensor and the ELISA test, providing
further evidence of the reliability of the proposed approach.
The LOD values for the μPAD and the commercial ELISA kit
were 3 and 39 pg mL−1, respectively. Moreover, the precision
of the method was evaluated using CD81 standards. The
within-assay precision was tested by five measurements on the
same day. These analyses were repeated for 3 consecutive days
to estimate the between-assay precision. The developed
immunosensor showed good precision; the CV within-assay
values were below 3.78%, and the between-assay values were
below 6.12%. Besides, a lower analysis time (20 min) and a
wide linear concentration range for both biomarkers were
noted for the μPAD (Table 1), compared with the ELISA test.
Additionally, the sensor’s stability was also evaluated, and
this was accomplished by storing the sensor for 1 month at 4
°C. No significant loss of sensitivity (less than 5%) was noticed
after the storage compared to the response just after
Figure 4. SEM (a) and TEM (b) images of the SBA-15. N2 adsorption−desorption isotherm of SBA-15 at 77 K (c). FTIR spectra of SBA-15 and
amino functionalized SBA-15 (d).
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Figure 5. Morphological characterization of the rGO working electrode by SEM (a), energy-dispersive spectra of (I) GO and (II) rGO (b). Cyclic
voltammogram recorded with the rGO electrode in 1 mmol L−1 catechol + 0.1 mol L−1 phosphate−citrate buffer pH 5.00 at 75 mV s−1 (c), and the
plot of the square root of the scan rate on the peak current (d).
Figure 6. Correlation plot between results obtained with the dual electrochemical paper-based immunosensor and the commercial ELISA kit for
Claudin 7 (a) and CD81 (b).
Table 1. Comparison of the Analytical Performance of the Commercial ELISA Kit and the Dual Electrochemical Paper
Immunosensor (EI) for Each BC Biomarker
method time (min) CV %a within-assay CV %a between-assay CV %a linear range LOD
ELISAClaudin 7 270 6.85 9.89 7.32 15.1−1000b 3.9b
EIClaudin 7 20 3.96 6.14 3.75 2−1000b 0.4b
ELISACD81 270 4.93 8.32 6.65 0.15−10c 0.039c
EICD81 20 3.78 6.12 3.66 0.01−10c 0.003c
aFive replicates (n = 5). bpg mL−1 claudin 7. cng mL−1 CD 81.
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fabrication. Moreover, the selectivity was investigated against
EV samples with other cancer biomarkers such as EPCAM,
EGFR, CEA, and CA 15-3 in 10-fold concentrations compared
to that of CD81 and Claudin 7. As shown in Supporting
Information 10, the presence of these interfering compounds
caused negligible changes in the response (less than 2%).
Hence, the results indicated a strong ability of the developed
immunosensor to avoid interferences, which is attributed to
the use of monoclonal antibodies and the blocking of
nonspecific adsorption on the surface. Finally, a comparison
of both paper and SBA-15/paper platforms was carried out to
assess the effectiveness of using the SBA-15 material. Results
shown in the Supporting Information 11 clearly confirm the
increased sensitivity obtained with the SBA-15/paper platform
owing to the enhanced surface to volume ratio.
Validation of Claudin 7 Determination and Claudin
7/CD81 Ratio. Eighty participants were recruited for
validation of the Claudin 7 biomarker: 20 healthy volunteers
and 60 BC patients (Figure 1 and Table S1). Values for
Claudin 7 and the Claudin 7/CD81 ratio were significantly
higher for patients with BC [n = 60, Claudin 7 median 83 nA,
interquartile range (IQR) 69.9−104.8 nA; mean 90.68 ± 28.4
SD; Claudin 7/CD81 ratio median 1.55 nA, IQR 1.22−2.19
nA; mean 1.971 ± 1.58 SD] compared to those of the healthy
control group (n = 20; Claudin 7 median 55 nA, IQR 29.53−
63.3 nA; mean 0.53.91 ± 29.62 SD; Claudin 7/CD81 ratio
median 0.594, IQR 0.22−0.71, mean 0.67 ± 0.4582 SD)
(Figure 7). These data suggest that Claudin 7 and the Claudin
7/CD81 ratio are excellent biomarkers for early BC diagnosis.
In addition, levels of Claudin 7 and the Claudin 7/CD81
ratio did not correlate with the tumor’s size (for Claudin 7,
Pearson r = 0.058; p = 0.65 and for Claudin 7/CD81 ratio,
Pearson r = 0.121; p = 0.35). Moreover, Claudin 7 and the
Claudin 7/CD81 ratio levels showed no significant correlation
Figure 7. CEA, CA15.3, Claudin 7, and Claudin 7/CD81 levels (a−d) in plasma in the validation set of patients and healthy volunteers (n = 60 and
n = 20 respectively). ROC curves of CEA, CA15.3, Claudin 7, and Claudin 7/CD81 ratio (e−h) for the assessment of diagnosis accuracy of BC.
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with age, menopause status, grade, Ki-67, and status of ER, PR,
and Her2 (p > 0.05; Table 2). Similar results were obtained in
a previous study, where the Claudin 7 concentration was
determined in the tissues of BC patients.40
By analysis of ROC curves, an optimum diagnostic cutoff of
95.75 nA was observed for Claudin 7 [area under the curve
(AUC), 0.8517; 95% confidence interval (CI) = 0.732−0.971;
sensitivity at 95% specificity, 75.13%] and an optimum
diagnosis cutoff of 0.9885 for the Claudin 7/CD81 ratio
(AUC, 0.8908; 95% CI = 0.796−0.985; sensitivity at 90%
specificity, 90%). In the assessment of differential accuracy,
Claudin 7 and the Claudin 7/CD81 ratio showed higher AUC
values (0.8517 ± 0.06 SD for Claudin 7 and 0.8908 ± 0.048
SD for Claudin 7/CD81 ratio) than classical serum markers as
CEA (AUC, 0.5217 ± 0.068 SD) and CA 15.3 (AUC, 0.7683
± 0.0056 SD). Indeed, as expected, the Claudin 7/CD81 ratio
showed slightly higher accuracy than only Claudin 7 by
comparing AUC values (Figure 7).
In this work, we have demonstrated that the identification of
tumor specific markers in the total bulk of circulating EVs can
be useful to improve BC diagnosis.41 EVs contain disease-
associated proteins and transport important information from
the cells of origin.42 The characterization of plasma-isolated
EVs has two important advantages compared to circulating
biomarkers in total plasma. First, lipid membranes of EVs
protect their cargo from proteases. Moreover, a reduction in
the proteome complexity of the biological fluids is expected
when EVs are isolated by SEC.43 Additionally, RPPA analysis
of EVs has been a remarkable tool to identify specifically EVs
associated with cancer biomarkers with excellent sensitivity.
The focus was directed toward specific markers of epithelial
tissue, but such proteomic studies can identify other
biomarkers. Recently, in agreement with our work, Claudin 7
has been identified as a diagnostic marker in serum from colon
cancer patients.44 In the last years, new diagnostic method-
ologies and the improvement of primary antibodies have
facilitated identifying new proteins as a diagnostic marker. In
our case, thanks to the employed nanomaterials, we developed
a dual immunosensor with excellent sensitivity to determine
both Claudin 7 and CD81. The use of paper and graphite as
materials for chip fabrication reduces economic cost. This kind
of chips has multiple advantages such as affordability, facile
disposability, portability, and simple fabrication, facilitating
mass production.23,28 Moreover, multiplexing these devices
enables the simultaneous execution of multiple assays on a
single device without cross-contamination.16 In our work, we
employed this dual paper chip in a validation set of 60 patients,
and we demonstrated that Claudin 7 and the Claudin 7/CD81
ratio can drastically improve the early BC diagnosis compared
with classical markers used in standard methodologies. Besides,
the normalization with CD81 guarantees that Claudin 7
variations are due to the number of epithelial EVs and not
caused by a change in the number of total EVs.45 We did not
observe any other relation with the clinical outcomes of
patients and Claudin 7 determination in EVs. Curiously, the
release of Claudin 7 in EVs did not correlate with tumor size,
possibly because the size differences were not large enough.
Another possible explanation is that Claudin 7 is a protein
involved in focal adhesion, and its release is more related to
cellular reorganization than in cellular growth.46,47 In any case,
this marker should be validated in a higher number of patients,
different stages of the disease as locally invasive or metastatic
BC, and/or other diseases that could be related with false
positives. Besides, this methodology must be validated by in
vitro and in vivo models or risk population screening to predict
BC earlier. At the moment, we can say that this analysis is
highly specific, highly sensitive, simple, and cheap. Future
studies must demonstrate prognostic and predictive value as
well as suitability as a monitoring tool.
■ CONCLUSIONS
Based on the results of this study, we demonstrated the
following: (i) circulating EVs represent a valuable sample to be
used in early diagnosis of BC. (ii) Claudin 7 has been
identified as the most significant epithelial protein expressed in
EVs and validated as a BC diagnosis marker. (iii) CD81 is a
suitable normalizer of EV markers in plasma, improving the
accuracy of Claudin7 for BC diagnosis. (iv) Both Claudin 7
and Claudin 7/CD81 ratio have better accuracy than classical
circulating markers as CEA and CA 15.3 for early diagnosis of
BC.
We also demonstrated that our dual sandwich-type electro-
chemical paper-based immunosensor has a shorter overall
assay time (20 min) than the one usually employed in the
commercial ELISA test kits (270 min) for both biomarkers,
with no reduction on the sensitivity and specificity. Finally, the
paper-based immunosensor demonstrated to be highly specific
(due to the use of monoclonal antibodies), sensitive (10-fold
for Claudin 7 and 13-fold for CD81 in comparison with their
respective ELISA test), simple, and cheap (12 times cheaper
than the ELISA test), improving significantly the accuracy of
early diagnosis of BC.
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Table 2. Correlation between Claudin 7 Determination and Clinical Relevant Data of Enrolled Patients
age menopause status grade estrogens receptor progesterone receptor Her2 Ki-67 (%)
Pearson r
Claudin 7 0.077 0.141 0.058 0.101 0.0646 0.133 0.017
Claudin 7/CD81 0.067 0.101 0.121 0.033 −0.061 0.068 0.044
P Values
Claudin 7 0.554 0.281 0.658 0.440 0.626 0.334 0.901
Claudin 7/CD81 0.610 0.439 0.356 0.802 0.645 0.621 0.749
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T e ́ c n i c a s ( C O N I C E T ) ( A r g e n t i n a ) ( P I P
11220150100004CO), from GENYO, Centre for Genomics
and Oncological Research: Pfizer-University of Granada,
Andalusian Regional Government (Granada, Spain), and the
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(31) Theŕy, C.; Witwer, K. W.; Aikawa, E.; Alcaraz, M. J.; Anderson,
J. D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.; Atkin-
Smith, G. K.; Ayre, D. C.; Bach, J. M.; Bachurski, D.; Baharvand, H.;
Balaj, L.; Baldacchino, S.; Bauer, N. N.; Baxter, A. A.; Bebawy, M.;
Beckham, C.; Bedina Zavec, A.; Benmoussa, A.; Berardi, A. C.;
Bergese, P.; Bielska, E.; Blenkiron, C.; Bobis-Wozowicz, S.; Boilard,
E.; Boireau, W.; Bongiovanni, A.; Borras̀, F. E.; Bosch, S.; Boulanger,
C. M.; Breakefield, X.; Breglio, A. M.; Brennan, M.; Brigstock, D. R.;
Brisson, A.; Broekman, M. L. D.; Bromberg, J. F.; Bryl-Goŕecka, P.;
Buch, S.; Buck, A. H.; Burger, D.; Busatto, S.; Buschmann, D.;
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Serrano, M. J. Sci. Rep. 2020, 10, 3974.
(44) Xu, C.; Wang, X.; Li, W.; Wang, K.; Ding, L. Technol. Canc. Res.
Treat. 2018, 17, 1533033818817774.
(45) Kowal, J.; Arras, G.; Colombo, M.; Jouve, M.; Morath, J. P.;
Primdal-Bengtson, B.; Dingli, F.; Loew, D.; Tkach, M.; Theŕy, C. Proc.
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